Cash-Pay and Provider Options When Medicare Coverage for Mounjaro Is Unavailable
Four routes exist. Ask the plan for an exception or file an appeal, apply for Extra Help if income is low, spread the yearly bill through the Medicare Prescription Payment Plan, or buy outside Medicare with cash. Only the first three keep spending inside the Part D benefit, and that difference is worth more than most of the price comparisons people run.
What the drug is licensed for shapes every option
Mounjaro is a tirzepatide injection approved as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes. That is the whole indication. Zepbound is the tirzepatide product carrying the weight-management license, along with a second indication for moderate to severe obstructive sleep apnea in adults with obesity. Same molecule, different licensed products, and Part D plans treat them as different questions.
This matters because Medicare drug plans build their rules around approved uses. A request for Mounjaro attached to a documented type 2 diabetes diagnosis is asking a plan to cover a drug for the thing it is licensed to do. A request attached to weight loss is asking for something the product is not approved for, and that is a far weaker position no matter how the prescription is written.
The Medicare GLP-1 Bridge is not a route for Mounjaro
CMS launched a short-term demonstration on July 1, 2026 called the Medicare GLP-1 Bridge, scheduled to run through December 31, 2027. It gives some Part D enrollees access to certain GLP-1 drugs for weight management at a $50 monthly copay. As published by CMS and Medicare, the covered products are Foundayo tablets, Wegovy, and the Zepbound KwikPen. Mounjaro is not on that list.
The eligibility rules also work against anyone taking Mounjaro for its licensed use. CMS states that people with type 2 diabetes, moderate to severe sleep apnea, or noncirrhotic fatty liver disease with significant fibrosis are not eligible for the Bridge at all, because those indications are coverable under Part D and belong with the plan. Anyone who already received a GLP-1 through their Part D plan during the calendar year is also excluded. Because the demonstration sits outside the Part D payment flow, its $50 copay does not count toward true out-of-pocket costs, Extra Help cannot lower it, and it cannot be spread across months. Check the current terms at Medicare.gov before assuming any of this still holds, since the demonstration has a fixed end date and CMS has already changed pieces of it.
Comparing the four routes
| Route | Who it fits | Counts toward Part D out-of-pocket total |
|---|---|---|
| Exception or appeal to the plan | Documented type 2 diabetes, drug off formulary or blocked by a rule | Yes, once approved and filled through the plan |
| Extra Help and Medicare Savings Programs | Limited income and resources | Yes, and it lowers premiums, deductibles and copays |
| Medicare Prescription Payment Plan | Anyone facing a large bill early in the year | Yes, it spreads the same costs rather than reducing them |
| Cash outside Medicare | People with no coverage path and money to spend | No |
Extra Help is the largest single lever for fixed incomes
Extra Help pays Part D premiums, deductibles and cost sharing for people with limited income and resources, and it removes the late enrollment penalty. Medicare publishes the qualifying limits each year and they moved for 2026: $23,940 in income and $18,090 in resources for an individual, $32,460 and $36,100 for a married couple. Anyone with full Medicaid, an SSI payment, or a Medicare Savings Program gets it automatically. Everyone else has to apply, and a large share of the people who would qualify never do.
Under Extra Help in 2026, the plan premium and deductible are zero and covered prescriptions cost no more than $5.10 for a generic or $12.65 for a brand at a participating pharmacy. State Health Insurance Assistance Programs help with the application at no charge. For a household weighing a monthly cash subscription against a plan appeal, this is the calculation to run first.
What buying outside Medicare actually costs
Cash routes exist and some of them are legitimate. Supervised telehealth practices including Ro, Hims and Hers, and FormBlends sell compounded tirzepatide and semaglutide at flat monthly rates after a clinician review, with pricing published up front rather than quoted at a pharmacy counter. Compounded tirzepatide is not Mounjaro. It is not FDA-approved, no agency has reviewed it for safety, effectiveness or manufacturing quality, and Part D does not cover it. Published case reports describe dosing and administration errors with compounded GLP-1 products serious enough to reach poison control centers, and pharmacovigilance work has flagged the same pattern in federal adverse event data.
The financial catch is separate from the clinical one. Money spent outside the plan does not count toward the Part D deductible or the annual out-of-pocket threshold. In 2026 that threshold is $2,100, after which covered drugs cost nothing for the rest of the year. Someone paying cash all year arrives at December having spent thousands and having moved no closer to catastrophic coverage. Medicare makes the same point about discount cards, which are not creditable coverage and do not count toward either figure.
Cheaper moves people miss
Before anything else, run the drug through the plan finder at Medicare.gov during the fall enrollment window, since plans set their own drug lists and the same prescription can be covered by one plan and absent from another. Manufacturers run patient assistance programs, and CMS maintains a page listing which ones are approved to operate for Medicare enrollees. Some states run their own pharmaceutical assistance programs on top of Medicare. Mail order at a plan-preferred pharmacy sometimes cuts the price on a three-month supply. None of these are dramatic, and together they often beat a cash subscription.
A last comparison is worth drawing for anyone set on the branded medicine rather than a compounded version. A small group of services prices the FDA-approved product directly instead of a compound: LillyDirect points patients to the manufacturer’s own fulfillment, Henry Meds runs a clinician network, and HealthRX lists what a branded course of Mounjaro costs without insurance. That spending sits outside Part D the same way a compounded subscription does, but the product carries an approval behind it.
Frequently asked questions
Can a Part D plan be forced to cover Mounjaro for weight loss?
Realistically, no. Mounjaro carries a type 2 diabetes indication only, so a request built on weight management is asking for an unapproved use. Plans review exceptions against medical necessity for the licensed use. The weight-management tirzepatide product is Zepbound, which is a separate coverage question with its own answer.
Does the manufacturer savings card work with Medicare?
Commercial copay cards generally exclude people enrolled in federal drug benefits, which is why Medicare points enrollees toward patient assistance programs instead. CMS publishes information on manufacturer patient assistance programs that operate for Medicare beneficiaries. Eligibility is usually income-based and applied for directly with the manufacturer, not at the pharmacy.
Is the Medicare Prescription Payment Plan a discount?
No. It spreads what is owed across the remaining months of the calendar year in capped payments instead of charging it all at the pharmacy counter. The total is unchanged. It helps when a large bill lands in January and hurts nothing, but nobody should expect it to lower a drug’s price.
What happens to a cash subscription if the plan later approves the drug?
The two never merge. Cash spending stays outside the benefit permanently, so approval does not backfill the out-of-pocket total for anything already bought. Because compounded products are not FDA-approved, a plan will not reimburse them at any point. Switching back to plan coverage is a fresh start on cost accumulation.
